Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal
allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match,
receiving immunosuppressive therapy with A) Zenapax® (5 doses), CellCept® (1.5 g bid., aiming
for TDM for total trough concentrations of 2-6 mg/L) and prednisolone or B) Sandimmun Neoral®
(full dose), CellCept® (1.0 g bid.) and prednisolone.